Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (541-550 of 755) with videos related to

Pageof 76
Sort By:
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Rheumatology (Oxford, England)|June 1, 2016
Calcinosis in systemic sclerosis: subsets, distribution and complicationsFrancesca Bartoli, Ginevra Fiori, Francesca Braschi, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Annals of the Rheumatic Diseases|July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritisJ van Holten, K Pavelka, J Vencovsky, et al.
The Lancet. Rheumatology|January 30, 2024
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Silvia Bellando-Randone, Francesco Del Galdo, Gemma Lepri, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseasesYu Fan, Miaotong Su, Lijun Yu, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Pageof 76

Showing results (541-550 of 755) with videos related to

Sort By:
Pageof 76
Arthritis and Rheumatism|December 1, 2007
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysisEdward Keystone, Roy Fleischmann, Paul Emery, et al.
Rheumatology (Oxford, England)|June 1, 2016
Calcinosis in systemic sclerosis: subsets, distribution and complicationsFrancesca Bartoli, Ginevra Fiori, Francesca Braschi, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
Annals of the Rheumatic Diseases|September 26, 2007
Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna, D J Lovell, E Giannini, et al.
Arthritis and Rheumatism|May 28, 2010
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisJ R Seibold, C P Denton, D E Furst, et al.
Annals of the Rheumatic Diseases|July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritisJ van Holten, K Pavelka, J Vencovsky, et al.
The Lancet. Rheumatology|January 30, 2024
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Silvia Bellando-Randone, Francesco Del Galdo, Gemma Lepri, et al.
Annals of the Rheumatic Diseases|May 30, 2026
Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseasesYu Fan, Miaotong Su, Lijun Yu, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Pageof 76